Croma-Pharma: Further strengthening its portfolio with PhilArt biostimulators

VIENNA, March 30, 2023 /PRNewswire/ — Croma (Croma-Pharma® GmbH) is a global player and challenger in the dynamically growing, minimally invasive aesthetics market and a leading manufacturer of premium quality hyaluronic acid (HA) syringes. With the launch of PhilArt, a complete series of injectable skin boosters, Croma is now further broadening its already comprehensive portfolio. Skin boosters are an important pillar of a minimally invasive aesthetics portfolio, next to HA fillers, botulinum toxin and PDO threads, allowing for combination therapies and a full-face approach. Read More

Contact:
Uschi Mayer
External Communications & PR
CROMA-PHARMA GmbH
Cromazeile 2, A-2100 Leobendorf, Austria
M.: +43 676 84 68 68 966
E: [email protected]

Logo: https://mma.prnasia.com/media2/2044449/Croma_Pharma_Logo.jpg?p=medium600

Subscribe on LinkedIn

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.